Coping as a Family: Discussing Duchenne with Loved Ones
This resource presents advice and resources on how to communicate a Duchenne diagnosis to your family and children.

This resource presents advice and resources on how to communicate a Duchenne diagnosis to your family and children.

An interactive presentation focused on harnessing creativity in day-to-day life with inclusive activities, games and exercises, as well as utilizing adaptive technology/equipment to surpass expectations.
CureDuchenne Certified Physical Therapist
CureDuchenne Physical Therapy Program
Occupational Therapist III
Children’s Health and Rehabilitation Services
Quantum Product & Technical Education Manager
Pride Mobility
Paul, Debra and Hawken Miller discuss FUTURES 2022, current advancements in therapies and next generation investments as well as programs CureDuchenne offers to improve the quality of life for those impacted by Duchenne.
This is a pre-recorded webinar with CureDuchenne, NS Pharma and guest speaker Dr. Mathula Thangarajh.
Topics include:
• Clinical evidence to support early initiation of DMD treatment
• The role of exon skipping in the treatment of DMD
• The efficacy of VILTEPSO for the treatment of DMD
• The safety and tolerability profile of VILTEPSO
This webinar, in partnership with the University of Kansas Medical Center, explores topics like achieving milestones, quality of life, and setting goals in families navigating Duchenne muscular dystrophy. The panelists also discuss how to incorporate quality of life metrics into clinical care.
Professor of Neurology
University of Kansas Medical Center
Clinical Assistant Professor
University of Kansas Medical Center
Medical Student
University of Kansas Medical Center
An overview of CureDuchenne Link.
Senior Director of Clinical Operations | Director, CureDuchenne Link
CureDuchenne
Hear from CureDuchenne’s Chief Scientific Advisor on our research support and priorities.
Wave will provide an overview of initial clinical trial results for WVE-N531 in individuals with Duchenne muscular dystrophy who are amenable to exon 53 skipping, as well as an overview of the potentially registrational FORWARD-53 study.
Chief Development Officer
Wave Life Sciences
¿Que sigue? Discusión sobre tecnología de próxima generación.